公司股票自2025年9月22日(星期一)开市起停牌一天，将于2025年9月23日(星期二)开市起复牌。公司股 票自2025年9月23日(星期二)开市起被实施其他风险警示，股票简称由"创意信息"变更为"ST创意"。 智通财经APP讯，创意信息(300366.SZ)公告，公司于2025年9月19日收到中国证券监督管理委员会四川 监管局出具的《行政处罚事先告知书》,公司股票将被实施其他风险警示。 该告知书载明公司涉嫌违法的事实为："2022年11月，创意信息分别与国网四川综合能源服务有限公司 开展协同一体机销售业务、与四川中电启明星信息技术有限公司开展大数据平台硬件及软件销售业务。 创意信息从事上述业务时不具有对商品的控制权，在知悉业务交易模式的情形下仍采用总额法确认收 入，不符合《企业会计准则第14号--收入》(财会[2017]22号)第三十四条的规定，导致公司2022年年度报 告、2023年半年度报告分别多计营业收入2.68亿元、1.25亿元，分别占当期报告记载营业收入的 12.22%、15.84%。" ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. faces a fine of 3.1 million yuan due to revenue recognition violations, with ongoing losses in recent years amid industry competition [1][2]. Group 1: Regulatory Issues - The violation dates back to October 25, 2024, when the company received a notice from the China Securities Regulatory Commission (CSRC) regarding suspected illegal information disclosure [2]. - Guangji Pharmaceutical's subsidiary, Hubei Guangji Jikang Pharmaceutical Co., Ltd., improperly recognized revenue using the gross method instead of the net method, leading to inflated revenue figures for the first three quarters of 2022 [2]. - The Hubei Securities Regulatory Bureau plans to impose a fine of 1.5 million yuan on the company, with additional fines of 800,000 yuan each for the chairman and the CFO [2]. Group 2: Financial Performance - Guangji Pharmaceutical has reported continuous losses, with a net loss of 140 million yuan in 2023, which expanded to 295 million yuan in 2024, and a further loss of 36.26 million yuan in the first quarter of 2025 [5][6]. - The company attributes its losses to increased R&D investments, intensified industry competition, and low market prices for its main products, particularly feed-grade vitamins B2 and B12 [5][6]. - The company has acknowledged that its production capacity from recent acquisitions has not been fully utilized, contributing to high costs and operational expenses [5]. Group 3: Company Response and Future Strategies - Following the revenue recognition issue, the company plans to enhance its internal controls and financial management practices to prevent future violations [6]. - Guangji Pharmaceutical is focusing on improving the competitiveness of its main products and optimizing its existing assets to mitigate losses [6]. - The company is also undergoing management reforms to address the challenges posed by low market prices and shrinking demand [6].